End-
Conditions
Interventions
Receiving oral furosemide 500 mg after breakfast and lunch (a total dose of furosemide 1000 mg/day),Receiving oral furosemide 500 mg after breakfast and oral placebo 1 capsule after lunch (a total dos
Experimental Drug,Active Comparator Drug
Oral furosemide 1000 mg/day,Oral furosemide 500 mg/day
Sponsors
Division of nephrology
Chiang Mai University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Adults aged 18–80 years old 2. ESRD patients treated with PD at least 1 month 3. No history of PD related peritonitis within 1 month 4. No history of membrane failure or ultrafiltration failure
Exclusion criteria
Exclusion criteria: 1. Patients with hypotension (mean arterial blood pressure < 65 mmHg) or orthostatic hypotension 2. Patients with clinical of fluid overload within 1 month exp. heart failure, generalized edema, pleural effusion or ascites from physical examination or imaging 3. Patients who use less than 125 mg or more than 1,000 mg per day of oral furosemide 4. Serum potassium less than 3.0 mEq/L 5. Serum albumin less than 2.5 g/dL 6. Patients using other diuretic drugs 7. Patients with contraindication for furosemide 8. Patients who have 24-hour urine volume less than 100 ml after the run-in phase of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-hour urine volume at 1 month after receiving intervention milliltre | — |
Secondary
| Measure | Time frame |
|---|---|
| Urinary sodium excretion at 1 month after receiving intervention measure sodium in 24-hour urine ,Renal clearance by using creatinine clearance and Kt/V of urea at 1 month after receiving intervention Calculate from measured creatinine and urea from blood and urine | — |
Contacts
Public ContactSurachet Vongsanim
Chiang Mai University
Outcome results
None listed